0. DOCID:31031 SCORE: 0.00315426429840296
DOCNO: 16340841
OWNER: NLM
STATUS: In-Data-Review
AUTHOR: J-P Sculier JP
AFFILIATION: Service des Soins Intensifs & Oncologie Thoracique, Institut Jules Bordet, Bruxelles, Belgique.
PUBTYPE: Journal Article
JOURNALTITLE: Revue des maladies respiratoires.
COUNTRY: France
TITLE: [Treatment of thoracic malignancy - results of meta-analyses.]
PUBDATE: 20051201
Meta-analyses dealing with the treatment of thoracic malignancy (non-small cell lung cancer, small cell lung cancer and mesothelioma) were reviewed including isolated ones, based on individual data from clinical trials, or conducted in the context of a systematic review of the literature Their results have changed clinical practice, notably by validating radiochemotherapy for patients with unresectable limited diseases, adjuvant chemotherapy for resectable non-small cell lung cancer and by identifying the most active drugs. However it is important to understand the limits of their methodology in order to avoid inappropriate interpretations.


1. DOCID:31466 SCORE: 0.00315424474461814
DOCNO: 16340841
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Meta-Analysis
QUALIFIER: therapy
AUTHOR: J-P Sculier JP
AFFILIATION: Service des Soins Intensifs & Oncologie Thoracique, Institut Jules Bordet, Bruxelles, Belgique. sculier@bordet.de
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Revue des maladies respiratoires.
COUNTRY: France
TITLE: [Treatment of thoracic malignancy--results of meta-analyses]
PUBDATE: 20051201
Meta-analyses dealing with the treatment of thoracic malignancy (non-small cell lung cancer, small cell lung cancer and mesothelioma) were reviewed including isolated ones, based on individual data from clinical trials, or conducted in the context of a systematic review of the literature Their results have changed clinical practice, notably by validating radiochemotherapy for patients with unresectable limited diseases, adjuvant chemotherapy for resectable non-small cell lung cancer and by identifying the most active drugs. However it is important to understand the limits of their methodology in order to avoid inappropriate interpretations.


2. DOCID:31860 SCORE: 0.00315422789816873
DOCNO: 16304042
OWNER: NLM
STATUS: In-Data-Review
AUTHOR: Ann A Shi AA
AUTHOR: Dianne Georgian-Smith D
AUTHOR: Felix S Chew FS
AFFILIATION: AVON Breast Comprehensive Center and Department of Radiology, Massachusetts General Hospital, WACC 219R, 15 Parkman St., Boston, MA 02114.
PUBTYPE: Journal Article
JOURNALTITLE: AJR. American journal of roentgenology.
COUNTRY: United States
TITLE: Imaging of the male breast: self-assessment module.
PUBDATE: 20051201
The educational objectives for this self-assessment module on male breast imaging are for the participant to exercise, self-assess, and improve his or her understanding of the evaluation and management of a breast mass presenting in a man; gain familiarity with the differential diagnosis of breast masses in men and how to evaluate such lesions by imaging; gain familiarity with the sonographic features of breast cancer in men; and gain familiarity with the imaging features of vascular tumors of the breast.


3. DOCID:31481 SCORE: 0.00224453429106614
DOCNO: 16328121
OWNER: NLM
STATUS: In-Process
AUTHOR: R Haberstich R
AUTHOR: J J Tuech JJ
AUTHOR: M Wilt M
AUTHOR: J F Rodier JF
AFFILIATION: Department of Surgical Oncology, Paul Strauss Cancer Institute, Strasbourg, France.
PUBTYPE: Journal Article
JOURNALTITLE: Techniques in coloproctology.
COUNTRY: Italy
TITLE: Anal localization as first manifestation of metastatic ductal breast carcinoma.
PUBDATE: 20051201
The incidence of extrahepatic gastrointestinal metastases from breast cancer is reported in the literature only as necroscopy studies (6-18%); they usually originate from lobular or a mixed ductal-lobular subtype. Nonspecific presenting symptoms, death of the patients caused by other more frequent metastases, and variable radiographic features mimicking primary neoplasms cause a clinical underestimation of this pathology. We report here a case of rectal metastasis from an invasive ductal carcinoma (IDC). This is to our knowledge, the first recorded instance of an anal metastasis from IDC.


4. DOCID:31624 SCORE: 0.00224451393375025
DOCNO: 16304559
OWNER: NLM
STATUS: In-Data-Review
AUTHOR: R Newton R
AUTHOR: T Ribeiro T
AUTHOR: D Casabonne D
AUTHOR: E Alvarez E
AUTHOR: A Touzé A
AUTHOR: T Key T
AUTHOR: P Coursaget P
AFFILIATION: 1Epidemiology & Genetics Unit, Department of Health Sciences, Area 3, Seebohm Rowntree Building, Heslington, York YO10 5DD, UK.
PUBTYPE: Journal Article
JOURNALTITLE: British journal of cancer.
COUNTRY: England
TITLE: Antibody levels against BK virus and prostate, kidney and bladder cancers in the EPIC-Oxford cohort.
PUBDATE: 20051101
In a case-control study nested within the EPIC-Oxford cohort, there were no statistically significant differences in the prevalence or titre of antibodies against BK virus measured in plasma taken prior to diagnosis between cases with cancer of the prostate (n=31), kidney (n=5) or bladder (n=9) and controls (n=45).British Journal of Cancer (2005) 93, 1305-1306. doi:10.1038/sj.bjc.6602869 www.bjcancer.com.


5. DOCID:31835 SCORE: 0.0022444847771058
DOCNO: 16399449
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: drug therapy
QUALIFIER: radiotherapy
AUTHOR: Bernard J Cummings BJ
AFFILIATION: Department of Radiation Oncology, Princess Margaret Hospital/University of Toronto, Toronto, Ontario M5G 2M9, Canada. Bernard.Cummings@rmp.uhn.on.ca
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Seminars in oncology.
COUNTRY: United States
TITLE: Current management of anal canal cancer.
PUBDATE: 20051201
Combined-modality therapy consisting of radiation therapy and 5-fluorouracil plus mitomycin remains the standard treatment for localized anal canal cancer, permitting preservation of organ function and achieving high response and survival rates. Current trials are evaluating the ability to deliver higher doses of radiation therapy over shorter intervals. Currently, the most common indication for radical surgery is failure of chemoradiation. Metastatic disease is less responsive to chemoradiation treatment. Neoadjuvant and adjuvant strategies are being evaluated, and additional drugs including capecitabine, irinotecan, and oxaliplatin are being assessed in treatment of localized and advanced disease.


6. DOCID:29364 SCORE: 0.00158648122282273
DOCNO: 15145243
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: pathology
QUALIFIER: therapy
AUTHOR: Jin-Woo Park JW
AUTHOR: Orlo H Clark OH
AFFILIATION: Department of Surgery, College of Medicine, Chungbuk National University, San 62 Kaeshin-dong, Heungdok-gu, Cheongju, 361-763 South Korea.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: The Surgical clinics of North America.
COUNTRY: United States
TITLE: Redifferentiation therapy for thyroid cancer.
PUBDATE: 20040601
Thyroid tumorigenesis and carcinogenesis accompany progressive loss of thyroid-specific differentiated functions. Some thyroid cancers are or become dedifferentiated, and they become refractory to efficacy-proven conventional therapies such as radioiodine ablation therapy and thyrotropin (TSH)-suppressive therapy. Redifferentiation therapy by either redifferentiating agents or gene transfer of differentiation-related genes may retard tumor growth and make tumors respond to conventional therapies.


7. DOCID:31738 SCORE: 0.00154954179673784
DOCNO: 16213720
OWNER: NLM
STATUS: In-Process
AUTHOR: Pui-Kai Li PK
AUTHOR: Zili Xiao Z
AUTHOR: Zhigen Hu Z
AUTHOR: Bulbul Pandit B
AUTHOR: Yanjun Sun Y
AUTHOR: Dan L Sackett DL
AUTHOR: Karl Werbovetz K
AUTHOR: Andrew Lewis A
AUTHOR: Jayasekar Johnsamuel J
AFFILIATION: Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA. li.27@osu.edu
PUBTYPE: Journal Article
JOURNALTITLE: Bioorganic & medicinal chemistry letters.
COUNTRY: England
TITLE: Conformationally restricted analogs of Combretastatin A-4 derived from SU5416.
PUBDATE: 20051201
A series of compounds originally derived from the vascular endothelial growth factor receptor tyrosine kinase inhibitor, SU5416, was synthesized and evaluated. The most potent compound in this series, compound 7, structurally resembles the potent anti-microtubule agent Combretastatin A-4, inhibited tubulin polymerization, and showed potent growth inhibitory activities on both prostate and breast cancer lines with IC(50) values in low to subnanomolar range.


8. DOCID:31006 SCORE: 0.00139977040759641
DOCNO: 11895754
AUTHOR: Niall O'Higgins N
AUTHOR: Bin B R Kroon BB
AFFILIATION: St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.
PUBTYPE: Comment
PUBTYPE: Journal Article
JOURNALTITLE: Bulletin du cancer.
COUNTRY: France
TITLE: Observations on surgical oncology and the Livre blanc.
PUBDATE: 20020201
A high standard of surgical care is the most crucial factor in determining outcome for the great majority of patients with solid malignant tumours. Although acknowledged by most experts this fact is insufficiently recognised by the medical community, by health administrators, by the lay public or by political decision-makers. Difficulty in appreciating the importance of quality in surgery may have come about because of the changing role of the surgeon in cancer care. While remaining the most important instrument in curative cancer treatment, surgery has been joined by other modalities active against malignant disease.


9. DOCID:30998 SCORE: 0.00139976809084328
DOCNO: 12094757
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Survival Analysis
QUALIFIER: statistics & numerical data
QUALIFIER: methods
AUTHOR: A B Troxel AB
AFFILIATION: Department of Biostatistics, Mailman School of Public Health, Columbia University, 622 W 168th Street, PH18W, New York, NY 10032, USA. atroxel@biostat.columbia.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Statistical methods in medical research.
COUNTRY: England
TITLE: Techniques for incorporating longitudinal measurements into analyses of survival data from clinical trials.
PUBDATE: 20020601
This article reviews existing approaches for joint analysis of longitudinal measurements, possibly measured with error or incompletely observed, and event-time data, possibly censored. The models take the form of selection or pattern-mixture models; estimation proceeds via the EM algorithm or Bayesian sampling techniques. The models are compared, their estimation and inferential procedures described, and advantages and disadvantages noted. Examples are discussed from several disease areas, including cancer and AIDS.


10. DOCID:29052 SCORE: 0.00139972926762244
DOCNO: 15640022
OWNER: NLM
STATUS: In-Process
AUTHOR: Jing-Hua Yan JH
AUTHOR: Qi-Nong Ye QN
AUTHOR: Cui-Fen Huang CF
AFFILIATION: Beijing Institute of Biotechnology, Beijing 100 850, China. jinghuayan@hotmail.com
PUBTYPE: Journal Article
JOURNALTITLE: Yi chuan = Hereditas / Zhongguo yi chuan xue hui bian ji.
COUNTRY: China
TITLE: [Advance in researches on BRCA1.]
PUBDATE: 20040501
BRCA1 is one of the most important breast cancer susceptibility genes. It plays key roles in DNA damage repair, cell cycle checkpoint regulation, gene transcription chromatin stability, and cell proliferation. In this paper, advance in basic researches on BRCA1 is reviewed, and the role of BRCA1 in cancer development and progression is discussed, that may facilitate potential clinical application of BRCA1.


11. DOCID:29334 SCORE: 0.00139972926692258
DOCNO: 16123581
OWNER: NLM
STATUS: In-Process
AUTHOR: Victoria L Tkacz VL
AUTHOR: Tanyifor M Tohnya TM
AUTHOR: William D Figg WD
AFFILIATION: College of Pharmacy, The Ohio State University, Columbus, USA.
PUBTYPE: Journal Article
JOURNALTITLE: Cancer biology & therapy.
COUNTRY: United States
TITLE: Cyclooxygenase-2 and angiogenesis in prostate cancer.
PUBDATE: 20050801
Chronic inflammation has been associated with resulting in malignancies in prostate cancer patients. In the May 2005 issue of Clinical Cancer Research, a study by Wang et al. demonstrates a relationship between COX-2 expression and the local chronic inflammation within prostate cancer and the increased angiogenesis. Confirming the existence and extent of this relationship is essential in the determination of therapeutic modalities for the prevention and treatment of prostate cancer.


12. DOCID:30189 SCORE: 0.00138903312663302
DOCNO: 12898035
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Polymerase Chain Reaction
QUALIFIER: diagnosis
QUALIFIER: genetics
QUALIFIER: diagnosis
QUALIFIER: genetics
QUALIFIER: genetics
AUTHOR: W-D Beecken WD
AUTHOR: D Jonas D
AFFILIATION: Klinik für Urologie und Kinderurologie der J.-W.-Goethe-Universität, Frankfurt am Main. beecken@em.uni-frankfurt.de
PUBTYPE: Journal Article
JOURNALTITLE: Der Urologe. Ausg. A.
COUNTRY: Germany
TITLE: [Polymerase chain reaction in the urinary diagnosis of bladder cancer]
PUBDATE: 20030701
The polymerase chain reaction (PCR) is a highly sensitive and specific method for the detection of genetic material. Over the last few years, this method has been used increasingly for the molecular detection of disease. This report demonstrates the use of PCR in the diagnosis of bladder cancer. The principles of the method are shown by describing the detection of p53, CD44 and telomerase, as well as in microsatellite analysis.


13. DOCID:29252 SCORE: 0.0013152833727005
DOCNO: 14756436
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Genetic Markers
QUALIFIER: diagnosis
QUALIFIER: blood
AUTHOR: Nigel P S Crawford NP
AUTHOR: Daniel W Colliver DW
AUTHOR: Susan Galandiuk S
AFFILIATION: Price Institute of Surgical Research, Department of Surgery, University of Louisville, Kentucky 40292, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Journal of surgical oncology.
COUNTRY: United States
TITLE: Tumor markers and colorectal cancer: utility in management.
PUBDATE: 20031201
Colorectal cancer (CRC) is a leading cause of morbidity and mortality. Although genetic testing can screen for rare hereditary CRC syndromes, there is no ideal means of screening for sporadic forms of CRC. This review will focus on markers that are currently used in the management of sporadic CRC and their limitations, as well as possible future clinical applications.


14. DOCID:29657 SCORE: 0.00110816419757729
DOCNO: 12509767
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: physiology
QUALIFIER: metabolism
QUALIFIER: physiology
AUTHOR: Patricia S Steeg PS
AFFILIATION: Women's Cancers Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA. steegp@mail.nih.gov
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Nature reviews. Cancer.
COUNTRY: England
TITLE: Metastasis suppressors alter the signal transduction of cancer cells.
PUBDATE: 20030101
Tumour metastasis is a significant contributor to death in cancer patients. Eight metastasis-suppressor genes that reduce the metastatic propensity of a cancer cell line in vivo without affecting its tumorigenicity have been identified. These affect important signal-transduction pathways, including mitogen-activated protein kinases, RHO, RAC and G-protein-coupled and tyrosine-kinase receptors. So how might we use this knowledge to improve the treatment of patients with cancer?